Fast Five Quiz: Non–Small Cell Lung Cancer (NSCLC) and RET Mutation

Liquid biopsies have been shown to detect not only oncogenic driver mutations for advanced NSCLC, but also RET mutations acquired as resistance alterations to targeted therapy. These mutations include RET V804 gatekeeper mutation; solvent front mutations G810S/R/C; and acquired alterations in other genes, such as EGFR, BRAF, and PIK3CA.

Tissue biopsies must be performed at disease progression in order to identify acquired mutations. However, tissue biopsies are limited, and a comprehensive genomic analysis may be the best method of detecting RET rearrangements.

RET rearrangements appear to be associated with a high risk for brain metastasis.

Learn more about NSCLC workup and diagnosis.

Medscape © 2022 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Maurie Markman. Fast Five Quiz: Non–Small Cell Lung Cancer (NSCLC) and RET Mutation - Medscape - Aug 22, 2022.